Klinisk Biokemi i Norden · 1 2020
| 11
Day 3 June 11
8:30 – 18:00
Keynote: Matthias Mann
(Max Planck Institute of Biochemistry)
Proteomics in clinical diagnostics.
PARALLEL SESSION 7
PARALLEL SESSION 8
PARALLEL SESSION 9
Endocrinology
• M Gurnell
(Great Britain) When
thyroid function tests don’t make
sense
• J Sagen
(Norway) Precision medi-
cine in diabetes
• H Vesper
(USA) CDC stand-
ardization program for steroid
hormones
• TBA
Proteomics – any clinical impact,
yet?
• O N Jensen
(Denmark)
TBA
• M Lalowski
(Finland)
TBA
• S Kjellstrøm
(Sweden)
TBA
• F Berven
(Norway)
TBA
Troponin testing in acute coronary
artery disease
• B Lindahl
(Sweden) One-hour
rule out algorithm for suspicion of
acute coronary syndrome
• N Mills
(Great Britain) Troponin
positive patients without ACS
• K M Aakre
(Norway) Troponin
analyses in the high sensitive era –
what service should the laboratory
provide?
• C Hansen
(Denmark) 30 min rule
out algorithm
Lunch Break
Poster Session
(speakers TBA)
Poster Session
(speakers TBA)
Poster Session
(speakers TBA)
THE LORENTZ ELDJARN PRIZE COMPETITION 2020
PARALLEL SESSION 10
WORKSHOP
PARALLEL SESSION 11
NFKK-session
• <TBA>
Ethics in the laboratory
(An interactive, case-based
discussion)
• B Solberg
(Norway)
• J J Jónsson
(Iceland)
• A Pahle
(Norway)
• J Magnussen
(Norway)
Hematology
• M Aune
(Norway) The challenge
– analysis of blood cells in body
fluids
• O Klingenberg
(Norway)
Hemoglobinopathies
• A Larsson
(Sweden) Image based
analyses in hematology. Experi-
ences with the HemoScreen™ point
of care instrument
• AB Ahmed
(Norway) The clinical
impact of the complete blood
count – what do we believe and
what do we know?
Day 4 June 12
8:30 – 12:50
Keynote: Patrick Bossuyt
(Amsterdam UMC)
Evaluating medical tests and the new EU IVDR.
PARALLEL SESSION 12
PARALLEL SESSION 13
PARALLEL SESSION 14
Analytical performance specifi-
cations
• E Theodorsson
(Sweden) Uncer-
tainty in laboratory medicine
• W Oosterhuis
(The Netherlands)
Total error or measurement
uncertainty?
• S Sandberg
(Norway) Analytical
performance specifications with
focus on clinical outcome
• A K Aarsand
(Norway) Biological
variation data: fit for purpose?
Bleeding disorders
• T Lindahl
(Sweden) Platelet
function tests in a patient with
suspected bleeding disorder
• E B Leinøe
(Denmark) Appli-
cation of next generation
sequencing in inherited bleeding
disorders
• A H Kristoffersen
(Norway) First
line coagulation tests in bleeding
disorders
• C Henriksson
(Norway) Labora-
tory investigation of deficiencies
of rare coagulation factor(s)
Vitamins, trace elements and
environmental toxins
• A-L B Monsen
(Norway) Essential
micronutrients and environmental
pollutants in Norwegian women
and infants
• M Averina
(Norway) Environ-
mental pollutants in the general
Norwegian population
• J Ø Odland
(Norway) Environ-
mental pollutants or diet - what is
the main problem for the fetus?
• TBA
